| Field | Specification |
|---|---|
| Target | |
| Alternative names | DNA mismatch repair protein Msh2; hMSH2; MutS protein homolog 2; MSH2 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human MSH2 recombinant protein (Position: Q337-N583). Human MSH2 shares 94% and 93% amino acid (aa) sequence identity with mouse and rat MSH2, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 6B4F7 is a mouse monoclonal antibody that recognizes DNA mismatch repair protein Msh2 in human samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 104.7 kDa, and the supplier reports an observed band at about 105 kDa.
MSH2 is a central DNA mismatch repair protein. It pairs with MSH6 to form MutSα, which recognizes single-base mismatches and small loops, or with MSH3 to form MutSβ, which recognizes larger loops. Loss of MSH2 causes microsatellite instability, and germline mutations are a major cause of Lynch syndrome.
| Target | DNA mismatch repair protein Msh2 (gene MSH2; UniProt P43246, human) |
|---|---|
| Clone | 6B4F7 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2b |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 104.7 kDa |
| Observed MW | 105 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells, human A549 cells, human COLO-320 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human laryngeal squamous cells carcinomas tissue, human liver cancer tissue, human serous adenocarcinoma of ovary tissue, human invasive urothelial carcinoma tissue, human colorectal adenocarcinoma tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): Caco-2 cells.
Immunogen
Recombinant human MSH2 fragment (Gln337–Asn583), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 94% and 93%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places DNA mismatch repair protein Msh2 in the nucleus and chromosome. Tissue expression noted by UniProt (human): Ubiquitously expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
